$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Dr. Belbin reported receiving personal fees from ADx NeuroSciences outside the submitted work. Dr. Alcolea reported receiving personal fees for advisory board services and/or speaker honoraria from Fujirebio-Europe, Roche, Nurtricia, Krka Farmacéutica, Zambon S.A.U., and Esteve outside the submitted work. Dr. Lleó has served as a consultant or at advisory boards for Fujirebio-Europe, Roche, Biogen, Grifols, and Nutricia outside the submitted work. Dr. Fortea reported receiving personal fees for service on the advisory boards, adjudication committees, or speaker honoraria from AC Immune, Novartis, Lundbeck, Roche, Fujirebio, and Biogen outside the submitted work. Drs. Alcolea, Belbin, LLeó, and Fortea report holding a patent for markers of synaptopathy in neurodegenerative disease (licenced to ADx, EPI8382175.0). No other disclosures were reported. All other authors have nothing else to disclose.